105394-80-7|KT-362 fumarate|1-(3,4-dihydrobenzo[b][1,4]thiazepin-5(2H)-yl)-3-((3,4-dimethoxyphenethyl)amino)propan-1-one fumarate|-范德生物科技公司

KT-362 fumarate

NMR下载 COA and HPLC MSDS下载
names：
1-(3,4-dihydrobenzo[b][1,4]thiazepin-5(2H)-yl)-3-((3,4-dimethoxyphenethyl)amino)propan-1-one fumarate
CAS号：
105394-80-7
MDL Number：
MF(分子式)： C26H32N2O7S MW(分子量)： 516.609
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	KT-362 fumarate
英文别名	KT-362; KT 362; KT362; KT-362 fumarate.
CAS号	105394-80-7
Inchi	InChI=1S/C22H28N2O3S.C4H4O4/c1-26-19-9-8-17(16-20(19)27-2)10-12-23-13-11-22(25)24-14-5-15-28-21-7-4-3-6-18(21)24;5-3(6)1-2-4(7)8/h3-4,6-9,16,23H,5,10-15H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InchiKey	YIVXAQUBENUHJC-WLHGVMLRSA-N
分子式 Formula	C26H32N2O7S
分子量 Molecular Weight	516.609
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	KT-362 fumarate(CAS:105394-80-7 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	KT-362 is a calcium channel antagonist, potassium channel antagonist and sodium channel antagonist. KT-362 is a new antiarrhythmic agent with vasodilating action on intracellular calcium mobilization of atrial muscle.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Ueyama N, Wakabayashi S, Tomiyama T. Change of mechanical activity to contraction from the relaxation induced by the intracellular Ca2+ antagonist KT-362; effects of alkylation of side chain, and substitution of 2,3,4,5-tetrahydro-1,5-benzothiazepine derivatives. Chem Pharm Bull (Tokyo). 1997 Nov;45(11):1761-6. PubMed PMID: 9396151.

[2]Tatsukawa Y, Arita M. Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: a comparison with gallopamil and ryanodine. Cardiovasc Drugs Ther. 1997 Jan;10(6):667-75. PubMed PMID: 9110109.

[3] Erker T. [Studies on the chemistry of thieno-annealed O,N- and S,N-containing heterocyclics. 9. Synthesis and calcium channel blocking action of theino-analogs of KT-362]. Arch Pharm (Weinheim). 1995 Apr;328(4):313-6. German. PubMed PMID: 7611826.

[4] Cheng YN, Kiyosue T, Arita M. Effects of KT-362, a new antiarrhythmic agent, on membrane ionic currents of guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1994 Sep;270(3):851-7. PubMed PMID: 7932196.

[5] Buljubasic N, Marijic J, Stowe DF, Gross GJ, Kampine JP, Bosnjak ZJ. Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604. PubMed PMID: 1724538.

6: Kodama I, Shibata S. Effects of KT-362, a new antiarrhythmic agent with vasodilating action on intracellular calcium mobilization of atrial muscle. J Pharmacol Exp Ther. 1991 Jul 1;258(1):332-8. PubMed PMID: 2072305.7: Sakata K, Karaki H. Effects of a novel smooth muscle relaxant, KT-362, on contraction and cytosolic Ca2+ level in the rat aorta. Br J Pharmacol. 1991 Jan;102(1):174-8. PubMed PMID: 1710524; PubMed Central PMCID: PMC1917876.8: Hester RK, Shibata S. KT-362 related effects on intracellular calcium release and associated clinical potential: arrhythmias, myocardial ischemia, and hypertension. Cardiovasc Drugs Ther. 1990 Oct;4(5):1345-54. Review. PubMed PMID: 2278870.9: Wakabayashi S, Mochizuki S, Tomiyama A, Shibata S. Effects of KT-362, a new calcium release blocker, on vascular selectivity and hemodynamic actions in anesthetized dogs. Jpn J Pharmacol. 1990 Sep;54(1):23-32. PubMed PMID: 2273645.10: Pieper GM, Gross GJ. Augmented vascular relaxation to KT-362 in diabetic rat aorta: comparison to diltiazem. J Cardiovasc Pharmacol. 1990 Sep;16(3):394-400. PubMed PMID: 1700209.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开